Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05034822 · ClinicalTrials.gov registry record · Phase 1
Study of Ruxolitinib Cream in Children With Atopic Dermatitis
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT05034822 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 29 participants.
The verdict
NCT05034822, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is an open-label maximum use trial to evaluate ruxolitinib safety, tolerability and blood levels after its topical application twice daily to affected areas (≥ 35% BSA) in pediatric participants with atopic dermatitis (AD) and to determine if its systemic bioavailability results in any adverse events.
Interventions
- DRUG Ruxolitinib cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2021-12-16 |
| Est. Completion | 2023-08-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05034822
The ClinicalTrials.gov registry entry for NCT05034822 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ruxolitinib cream is the first listed.
NCT05034822 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05034822 about?
NCT05034822 is a clinical study titled "Study of Ruxolitinib Cream in Children With Atopic Dermatitis". This is an open-label maximum use trial to evaluate ruxolitinib safety, tolerability and blood levels after its topical application twice daily to affected areas (≥ 35% BSA) in pediatric participants with atopic dermatitis (AD) and to determine if its systemic bioavailability results in any adverse ...
What is the current status of trial NCT05034822?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2021-12-16. Estimated completion is 2023-08-07.
What interventions are being tested in trial NCT05034822?
The interventions under investigation include: Ruxolitinib cream (DRUG).
Who is sponsoring clinical trial NCT05034822?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.